Rie Sugimoto

Dr. Rie Sugimoto


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2021 in Cancers
Verified
Journal Article
Open access
PDF file
HIHideki Iwamoto
Hideki Iwamoto
TNTakashi Niizeki
Takashi Niizeki
HNHiroaki Nagamatsu
Hiroaki Nagamatsu
KUKazuomi Ueshima
Kazuomi Ueshima
TNTakako Nomura
Takako Nomura
KJKurume Liver Cancer Study Group of Japan
Kurume Liver Cancer Study Group of Japan
BACKROUND: Not all patients with hepatocellular carcinoma (HCC) benefit from treatment with molecular targeted agents such as sorafenib. We investigated whether New-FP (fine-powder cisplatin and 5-fluorouracil), a hepatic arterial infusion chemotherapy regimen, is more favorable than sorafenib as an initial treatment for locally progressed HCC. METHODS: To avoid selection bias, we corrected the data from different facilities that did or did not perform New-FP therapy. In total, 1709 consecutive patients with HCC initially treated with New-FP or sorafenib; 1624 (New-FP, n = 644; sorafenib n = 980) were assessed. After propensity score matching (PSM), overall survival (OS) and prognostic factors were assessed (n = 344 each). Additionally, the patients were categorized into four groups: cohort-1 [(without macrovascular invasion (MVI) and extrahepatic spread (EHS)], cohort-2 (with MVI), cohort-3 (with EHS), and cohort-4 (with MVI and EHS) to clarify the efficacy of each treatment. RESULTS: New-FP prolonged OS than sorafenib after PSM (New-FP, 12 months; sorafenib, 7.9 months; p < 0.001). Sorafenib treatment, and severe MVI and EHS were poor prognostic factors. In the subgroup analyses, the OS was significantly longer the New-FP group in cohort-2. CONCLUSIONS: Local treatment using New-FP is a potentially superior initial treatment compared with sorafenib as a multidisciplinary treatment in locally progressed HCC without EHS.

5 October 2022 in Cancers
Verified
Journal Article
Open access
PDF file
HIHideki Iwamoto
Hideki Iwamoto
TNTakashi Niizeki
Takashi Niizeki
HNHiroaki Nagamatsu
Hiroaki Nagamatsu
KUKazuomi Ueshima
Kazuomi Ueshima
JTJoji Tani
Joji Tani
KJKurume Liver Cancer Study Group of Japan
Kurume Liver Cancer Study Group of Japan
Background: Systemic treatments are recommended for advanced hepatocellular carcinoma (HCC) in preserved liver function. However, their effects are unsatisfactory in some tumor conditions, particularly macrovascular invasion (MVI) including major portal vein tumor thrombus (PVTT). We compared the efficacy of hepatic arterial infusion chemotherapy (HAIC) regimens New-FP and sorafenib for various tumor conditions in preserved liver function. Methods: We retrospectively collected the data of 1709 patients with HCC who were treated with New-FP or sorafenib. Survival was assessed after propensity score matching. Subgroup analyses were conducted: cohort 1 (no MVI or extrahepatic spread (EHS)), cohort 2 (MVI only), cohort 3 (EHS only), cohort 4 (MVI and EHS), and cohort 5 (major PVTT). Results: The New-FP group had a longer median survival time (MST) than the sorafenib in the whole analysis (18 vs. 9 months; p < 0.0001). New-FP demonstrated a longer MST compared with sorafenib in cohort 2 and cohort 4. In cohort 5, the MST of the New-FP group was 16 months, while that of sorafenib was 6 months (p < 0.0001). For major PVTT-HCC, the response rate of New-FP was 73.0%. The MST of patients who achieved complete response with New-FP was 59 months. Conclusions: HAIC using New-FP is promising for patients with MVI- and major PVTT-HCC in preserved liver function.

12 December 2025 in Cancers
Verified
Journal Article
Open access
PDF file
YMYusuke Morita
Yusuke Morita
RSRie Sugimoto
Rie Sugimoto
MKMiho Kurokawa
Miho Kurokawa
YTYuki Tanaka
Yuki Tanaka
TSTakeshi Senju
Takeshi Senju
MTMasatake Tanaka
Masatake Tanaka
Objectives: To evaluate the prognosis and costs of gemcitabine + cisplatin + S-1 (GCS) versus gemcitabine + cisplatin + durvalumab (GCD), the standard of care for advanced cholangiocarcinoma, in a prospective observational study. Methods: We enrolled 52 patients who received GCS as first-line treatment from April 2020 to April 2024 and 44 patients who received GCD from March 2023 to April 2024. Overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) were examined. Propensity score matching (PSM) was performed to balance baseline characteristics between the two groups, and OS, PFS and ORR were then analysed in the matched cohorts. Drug costs were compared until the end of treatment. Results: OS was not significantly different between GCS and GCD at 18.6 months (95% confidence interval [CI]: 13.3–21.9) (p = 0.0935) versus 12.2 months (95% CI: 7.5–16). PFS was 10.2 months (95% CI: 6.5–13.8) versus 6.2 months (95% CI: 3.2–8.8) for GCS versus GCD, respectively (p = 0.0151). The ORR was also higher for GCS (36.5%) than for GCD (15.9%) (p = 0.0234). Twenty-seven patients were included in the PSM analysis, which showed no significant differences in OS or ORR, and better PFS for GCS (9.3 months, 95% CI: 7.4–21.1 versus 4.8 months, 95% CI: 2.7–8.8; p = 0.007). The cost of GCS versus GCD was $6350 (95% CI: 2300–9800) versus $97,200 (95% CI: 69,400–138,800) by treatment end (p = 0.0001). Conclusions: GCS was significantly less expensive than GCD and showed comparable OS and better PFS.

3 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
YMYusuke Morita
Yusuke Morita
RSRie Sugimoto
Rie Sugimoto
MKMiho Kurokawa
Miho Kurokawa
YTYuki Tanaka
Yuki Tanaka
TSTakeshi Senju
Takeshi Senju
MTMasatake Tanaka
Masatake Tanaka
Objectives: To evaluate the prognosis and costs of gemcitabine + cisplatin + S-1 (GCS) versus gemcitabine + cisplatin + durvalumab (GCD), the standard of care for advanced cholangiocarcinoma, in a prospective observational study. Methods: We enrolled 52 patients who received GCS as first-line treatment from April 2020 to April 2024 and 44 patients who received GCD from March 2023 to April 2024. Overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) were examined. Propensity score matching (PSM) was performed to balance baseline characteristics between the two groups, and OS, PFS and ORR were then analysed in the matched cohorts. Drug costs were compared until the end of treatment. Results: OS was not significantly different between GCD and GCS at 12.2 months (95% confidence interval [CI]: 7.5–16) versus 18.6 months (95% CI: 13.3–21.9) (p=0.0935). P FS was 6.26 months (95% CI: 3.2–8.8) versus 10.2 months (95% CI: 6.5–13.8) for GCD versus GCS, respectively (p=0.0151). The ORR was also better for GCD (36.5%) than for GCS (15.9%) (p=0.0234). Twenty-seven cases were included in the PSM analysis, which showed n o significant differences in OS and b etter PFS (6.3, 95% CI: 2.8–9.3 versus 11.4, 95% CI: 6.2–15.0; p=0.0142) and ORR (14.8% versus 40.7%; p=0.0309) for GCS versus GCD, respectively. The cost of GCD versus GCS was 113,472 ± 72,198 versus 4622 ± 3109 US dollars by treatment end (p=0.0001). Conclusions: GCS was significantly less expensive than GCD and showed comparable OS and better PFS and ORR.